Stolina M et al. |
Regulatory effects of osteoprotegerin on cellular and humoral immune responses. |
2003 |
Clin. Immunol. |
pmid:14697750
|
Kapczuk K et al. |
[Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. |
2003 |
Ginekol. Pol. |
pmid:12916277
|
Liu JZ et al. |
[Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. |
2003 |
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi |
pmid:12916296
|
Bendre MS et al. |
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. |
2003 |
Bone |
pmid:12919697
|
Tabb MM et al. |
Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. |
2003 |
J. Biol. Chem. |
pmid:12920130
|
Miyahira Y et al. |
Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. |
2003 |
J. Immunol. |
pmid:14662831
|
Seidlova-Wuttke D et al. |
Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. |
2003 |
Eur. J. Endocrinol. |
pmid:14514351
|
Dovio A et al. |
Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. |
2003 |
Clin. Cancer Res. |
pmid:12796409
|
Flick LM et al. |
Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. |
2003 |
J. Orthop. Res. |
pmid:12798068
|
Khapli SM et al. |
IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. |
2003 |
J. Immunol. |
pmid:12816992
|
Kawase Y et al. |
Bone malformations in interleukin-18 transgenic mice. |
2003 |
J. Bone Miner. Res. |
pmid:12817749
|
Bell NH |
RANK ligand and the regulation of skeletal remodeling. |
2003 |
J. Clin. Invest. |
pmid:12697730
|
Eghbali-Fatourechi G et al. |
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. |
2003 |
J. Clin. Invest. |
pmid:12697741
|
Enomoto H et al. |
Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. |
2003 |
J. Biol. Chem. |
pmid:12697767
|
Nakashima T et al. |
RANKL and RANK as novel therapeutic targets for arthritis. |
2003 |
Curr Opin Rheumatol |
pmid:12707582
|
Xing L et al. |
Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. |
2003 |
J. Bone Miner. Res. |
pmid:12568403
|
Cao J et al. |
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. |
2003 |
J. Bone Miner. Res. |
pmid:12568404
|
Johnson-Pais TL et al. |
Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. |
2003 |
J. Bone Miner. Res. |
pmid:12568416
|
Clohisy JC et al. |
RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. |
2003 |
J. Orthop. Res. |
pmid:12568950
|
Walsh MC and Choi Y |
Biology of the TRANCE axis. |
2003 Jun-Aug |
Cytokine Growth Factor Rev. |
pmid:12787563
|
Smith BB et al. |
A toxicity profile of osteoprotegerin in the cynomolgus monkey. |
2003 Sep-Oct |
Int. J. Toxicol. |
pmid:14555415
|
Findlay DM et al. |
The proliferation and phenotypic expression of human osteoblasts on tantalum metal. |
2004 |
Biomaterials |
pmid:14741587
|
Theoleyre S et al. |
Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor kappaB ligand and MAPK. |
2004 |
Biochim. Biophys. Acta |
pmid:14741739
|
Redlich K et al. |
Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. |
2004 |
Am. J. Pathol. |
pmid:14742260
|
Mogi M et al. |
Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. |
2004 |
J. Dent. Res. |
pmid:14742657
|
Heim M et al. |
The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of human primary bone marrow stromal cells. |
2004 |
Endocrinology |
pmid:14605006
|
Crotti TN et al. |
Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. |
2004 |
Biomaterials |
pmid:14607494
|
Vegni FE et al. |
Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis. |
2004 |
N. Engl. J. Med. |
pmid:14711922
|
Crisafulli A et al. |
Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. |
2004 |
J. Clin. Endocrinol. Metab. |
pmid:14715848
|
Kubota A et al. |
Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. |
2004 |
J. Rheumatol. |
pmid:14994384
|
Kötter I and Stübiger N |
Therapeutic implications for interferon-alpha in arthritis. |
2004 |
J. Rheumatol. |
pmid:14994421
|
Schett G et al. |
Soluble RANKL and risk of nontraumatic fracture. |
2004 |
JAMA |
pmid:14996780
|
Lowe CE et al. |
Cost-effective analysis of candidate genes using htSNPs: a staged approach. |
2004 |
Genes Immun. |
pmid:15029236
|
Brown JM et al. |
Opg, RANKl, and RANK in cancer metastasis: expression and regulation. |
2004 |
Cancer Treat. Res. |
pmid:15043192
|
Tay JY et al. |
Identification of RANKL in osteolytic lesions of the facial skeleton. |
2004 |
J. Dent. Res. |
pmid:15044512
|
Doran PM et al. |
Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts. |
2004 |
Exp. Hematol. |
pmid:15050745
|
Kostenuik PJ et al. |
Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. |
2004 |
Bone |
pmid:15050896
|
Baek KH et al. |
Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism. |
2004 |
J. Clin. Endocrinol. Metab. |
pmid:15001618
|
Brage M et al. |
Osteoclastogenesis is decreased by cysteine proteinase inhibitors. |
2004 |
Bone |
pmid:15003789
|
Fukunaga J et al. |
Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. |
2004 |
Bone |
pmid:15003790
|
Sattler AM et al. |
Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. |
2004 |
Calcif. Tissue Int. |
pmid:14523602
|
Bergh JJ et al. |
Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. |
2004 |
Endocrinology |
pmid:14525906
|
Skoumal M et al. |
Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with Larsen score in rheumatoid arthritis. |
2004 |
Ann. Rheum. Dis. |
pmid:14722219
|
WÅ‚odarski KH et al. |
Influence of osteoprotegerin (OPG) on experimentally induced ectopic bone. |
2004 |
Folia Biol. (Krakow) |
pmid:19058561
|
Saidenberg-Kermanac'h N et al. |
Role for osteoprotegerin in rheumatoid inflammation. |
2004 |
Joint Bone Spine |
pmid:14769514
|
Abu-Amer Y et al. |
TNF receptor type 1 regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. |
2004 |
J. Cell. Biochem. |
pmid:15389885
|
Yang KC et al. |
[Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. |
2004 |
Zhong Nan Da Xue Xue Bao Yi Xue Ban |
pmid:16114553
|
Roux S and Mariette X |
The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression. |
2004 |
Leuk. Lymphoma |
pmid:15359989
|
Wittrant Y et al. |
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. |
2004 |
Biochim. Biophys. Acta |
pmid:15363860
|
Wada N et al. |
Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. |
2004 |
Bone |
pmid:15336598
|
Amato G et al. |
High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. |
2004 |
Bone |
pmid:15336617
|
Ono Y et al. |
Suppressive effect of Kanzo-bushi-to, a Kampo medicine, on collagen-induced arthritis. |
2004 |
Biol. Pharm. Bull. |
pmid:15340228
|
Farach-Carson MC et al. |
Integrating rapid responses to 1,25-dihydroxyvitamin D3 with transcriptional changes in osteoblasts: Ca2+ regulated pathways to the nucleus. |
2004 |
Steroids |
pmid:15288767
|
Vanderborght A et al. |
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. |
2004 |
J. Rheumatol. |
pmid:15290725
|
Soufi M et al. |
Osteoprotegerin gene polymorphisms in men with coronary artery disease. |
2004 |
J. Clin. Endocrinol. Metab. |
pmid:15292302
|
Schoppet M et al. |
Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. |
2004 |
J. Clin. Endocrinol. Metab. |
pmid:15292354
|
Lossdörfer S et al. |
Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. |
2004 |
J Biomed Mater Res A |
pmid:15293309
|
Kondo T et al. |
1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. |
2004 |
J. Bone Miner. Res. |
pmid:15312241
|
Kiefer JA et al. |
The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft. |
2004 |
Clin. Exp. Metastasis |
pmid:15672862
|
Kostenuik PJ |
Revisiting the seed and soil theory of bone metastasis: new tools, same answer. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15758267
|
Miyashita T et al. |
Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. |
2004 |
Clin. Exp. Immunol. |
pmid:15270863
|
Nociti FH et al. |
Cementoblast gene expression is regulated by Porphyromonas gingivalis lipopolysaccharide partially via toll-like receptor-4/MD-2. |
2004 |
J. Dent. Res. |
pmid:15271967
|
Hashimoto T et al. |
[Biochemical markers in bone metastasis]. |
2004 |
Gan To Kagaku Ryoho |
pmid:15272580
|
Oh KW et al. |
The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. |
2004 |
Clin. Endocrinol. (Oxf) |
pmid:15272921
|
Doi S et al. |
Increased serum osteoprotegerin level in older and diabetic hemodialysis patients. |
2004 |
Ther Apher Dial |
pmid:15274686
|
Stilgren LS et al. |
Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. |
2004 |
Bone |
pmid:15207766
|
Tsangari H et al. |
Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. |
2004 |
Bone |
pmid:15207775
|
Garlet GP et al. |
Matrix metalloproteinases, their physiological inhibitors and osteoclast factors are differentially regulated by the cytokine profile in human periodontal disease. |
2004 |
J. Clin. Periodontol. |
pmid:15257746
|
Baumann B et al. |
Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. |
2004 |
Acta Orthop Scand |
pmid:15260421
|
Tomek S et al. |
Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. |
2004 |
Gynecol. Oncol. |
pmid:15262127
|
Bord S et al. |
Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. |
2004 |
Br. J. Haematol. |
pmid:15238146
|
Essalihi R et al. |
Phenotypic modulation of vascular smooth muscle cells during medial arterial calcification: a role for endothelin? |
2004 |
J. Cardiovasc. Pharmacol. |
pmid:15838266
|
Hofbauer LC et al. |
Osteoprotegerin is highly expressed in the spinal cord and cerebrospinal fluid. |
2004 |
Acta Neuropathol. |
pmid:15106011
|
Suzuki T et al. |
Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL). |
2004 |
J. Bone Miner. Metab. |
pmid:15108059
|
Gonzalez-Calvin JL et al. |
Bone mineral density and serum levels of estradiol and osteoprotegerin in postmenopausal women with viral cirrhosis. |
2004 |
Gastroenterology |
pmid:15057779
|
Cheng Q et al. |
[Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women]. |
2004 |
Zhonghua Yi Xue Za Zhi |
pmid:15059506
|
Jang HD et al. |
PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit. |
2004 |
J. Biol. Chem. |
pmid:15140884
|
Granet C et al. |
Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. |
2004 |
Arthritis Res. Ther. |
pmid:15142264
|
Bengtsson AK et al. |
17beta-estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells. |
2004 |
Blood |
pmid:15142882
|
Golledge J et al. |
Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. |
2004 |
Stroke |
pmid:15143295
|
Seshasayee D et al. |
A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. |
2004 |
J. Biol. Chem. |
pmid:15145935
|
Yeung RS |
The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. |
2004 |
J. Rheumatol. |
pmid:15124240
|
Su X et al. |
[Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. |
2004 |
Zhong Nan Da Xue Xue Bao Yi Xue Ban |
pmid:16137047
|
Chondrogianni N et al. |
Cloning of differentially expressed genes in skin fibroblasts from centenarians. |
2004 |
Biogerontology |
pmid:15609104
|
Martinetti A et al. |
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. |
2004 |
Endocr. Relat. Cancer |
pmid:15613451
|
Whyte MP and Mumm S |
Heritable disorders of the RANKL/OPG/RANK signaling pathway. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615493
|
Hofbauer LC et al. |
The OPG/RANKL/RANK system in metabolic bone diseases. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615494
|
Ritchlin CT et al. |
RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615495
|
Clohisy DR and Mantyh PW |
Bone cancer pain and the role of RANKL/OPG. |
2004 |
J Musculoskelet Neuronal Interact |
pmid:15615497
|
Herrmann M and Herrmann W |
The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. |
2004 |
Clin. Chem. Lab. Med. |
pmid:15576300
|
Jono S |
[Risk factors of atherosclerosis in end-stage renal disease patients]. |
2004 |
Clin Calcium |
pmid:15576949
|
Wittrant Y et al. |
Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. |
2004 |
Exp. Cell Res. |
pmid:14729467
|
Hruska KA et al. |
Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy. |
2004 |
Semin. Nephrol. |
pmid:14730507
|
Zwerina J et al. |
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. |
2004 |
Arthritis Rheum. |
pmid:14730626
|
Mallat Z and Tedgui A |
Unbalanced RANKL/RANK pathway in aortic valve sclerosis. |
2004 |
J. Mol. Cell. Cardiol. |
pmid:14734042
|
Kaden JJ et al. |
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. |
2004 |
J. Mol. Cell. Cardiol. |
pmid:14734048
|
Itonaga I et al. |
Transforming growth factor-beta induces osteoclast formation in the absence of RANKL. |
2004 |
Bone |
pmid:14751563
|
Pan B et al. |
The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). |
2004 |
J. Bone Miner. Res. |
pmid:14753746
|
Valverde P et al. |
Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. |
2004 |
J. Bone Miner. Res. |
pmid:14753747
|
Buzi F et al. |
Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. |
2004 |
Clin. Endocrinol. (Oxf) |
pmid:14678293
|